Insignificance of surveillance imaging in patients with diffuse large B-cell lymphoma who achieved first complete remission: a retrospective cohort study

  • Takanori FukutaEmail author
  • Noriko Nishimura
  • Yuko Shirouchi
  • Norihito Inoue
  • Hideki Uryu
  • Yoshiharu Kusano
  • Yuko Mishima
  • Masahiro Yokoyama
  • Naoko Tsuyama
  • Kengo Takeuchi
  • Yasuhito Terui
Original Article


The aim of this study was to evaluate the value of scheduled imaging for patients who achieved first complete remission after CHOP-like chemotherapy plus rituximab. In this retrospective cohort study, we included 759 patients newly diagnosed with de novo diffuse large B-cell lymphoma (DLBCL) at the Cancer Institute, Japanese Foundation for Cancer Research. Relapsed patients were divided into two groups based on method of diagnosis: clinical symptoms (symptom group, n = 57) or scheduled imaging (imaging group, n = 27). Our primary goal was to compare overall survival and relapse-free survival between the two groups. No significant difference in outcomes was found between the symptom and imaging groups. Median overall survival [7.5 years; 95% confidence interval (CI) 4.0–9.7 vs. 9.1 years; 95% CI 2.7 to not reached; P = 0.747), and median relapse-free survival (1.8 years; 95% CI 1.4–2.5 vs. 2.4 years; 95% CI 1.2–4.4; P = 0.108). Surveillance imaging in patients with DLBCL who achieved first complete remission did not demonstrate an advantage in terms of overall survival or relapse-free survival.


Diffuse large B-cell lymphoma Surveillance imaging 


Author contributions

TF designed the study, reviewed the literature, wrote the initial draft of the manuscript, and chaired the writing group. NN, YS, and MY revised the manuscript, provided study materials, and approved the final draft of the manuscript. NT and KT diagnosed lymphoma. NI, HU, YK, YM, and YT provided study materials and approved the final draft of the manuscript.

Compliance with ethical standards

Conflict of interest

NN, YM, and MY are supported by Chugai-Roche Pharmaceuticals Co., Ltd. YT is supported by Bristol-Myers Squibb, Celgene, Janssen, Novartis Pharma, and Takeda Pharmaceutical Co., Ltd. The remaining authors declare no competing financial interests regarding this study.


  1. 1.
    Project TN-HsLC. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909–18.CrossRefGoogle Scholar
  2. 2.
    Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.CrossRefGoogle Scholar
  3. 3.
    Gogia A, Das CK, Kumar L, Sharma A, Tiwari A, Sharma M, et al. Diffuse large B-cell lymphoma: an institutional analysis. South Asian J Cancer. 2018;7:200.CrossRefGoogle Scholar
  4. 4.
    Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure—what to do? ASH Educ Progr Book. 2016;2016:366–78.Google Scholar
  5. 5.
    Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.CrossRefGoogle Scholar
  6. 6.
    Chaganti S, Illidge T, Barrington S, McKay P, Linton K, Cwynarski K, et al. Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol. 2016;174:43–56.CrossRefGoogle Scholar
  7. 7.
    Omachi K. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-overview. Int J Hematol. 2019;110:3–10.CrossRefGoogle Scholar
  8. 8.
    Morito T, Fujihara M, Asaoku H, Tari A, Sato Y, Ichimura K, et al. Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma. Cancer Sci. 2009;100:1255–60.CrossRefGoogle Scholar
  9. 9.
    Umino K, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, et al. Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2019;60:1926–33.CrossRefGoogle Scholar
  10. 10.
    Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.CrossRefGoogle Scholar
  11. 11.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.CrossRefGoogle Scholar
  12. 12.
    Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefGoogle Scholar
  13. 13.
    Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol. 2006;17:909–13.CrossRefGoogle Scholar
  14. 14.
    Petrausch U, Samaras P, Haile SR, Veit-Haibach P, Soyka JD, Knuth A, et al. Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy. Ann Oncol. 2010;21:1694–8.CrossRefGoogle Scholar
  15. 15.
    Hiniker SM, Pollom EL, Khodadoust MS, Kozak MM, Xu G, Quon A, et al. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era. Int J Radiat Oncol Biol Phys. 2015;92:99–106.CrossRefGoogle Scholar
  16. 16.
    Cheah CY, Hofman MS, Dickinson M, Wirth A, Westerman D, Harrison SJ, et al. Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer. 2013;109:312–7.CrossRefGoogle Scholar
  17. 17.
    Guppy AE, Tebbutt NC, Norman A, Cunningham D. The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma. Leuk Lymphoma. 2003;44:123–5.CrossRefGoogle Scholar
  18. 18.
    Avivi I, Zilberlicht A, Dann EJ, Leiba R, Faibish T, Rowe JM, et al. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Am J Hematol. 2013;88:400–5.CrossRefGoogle Scholar
  19. 19.
    Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol. 2014;32:3506–12.CrossRefGoogle Scholar
  20. 20.
    Lin TL, Kuo MC, Shih LY, Dunn P, Wang PN, Wu JH, et al. Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas. Ann Hematol. 2012;91:1741–5.CrossRefGoogle Scholar
  21. 21.
    Abel GA, Vanderplas A, Rodriguez MA, Crosby AL, Czuczman MS, Niland JC, et al. High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma. 2012;53:1113–6.CrossRefGoogle Scholar
  22. 22.
    Nabhan C, Smith SM, Cifu AS. Surveillance imaging in patients in remission from hodgkin and diffuse large B-cell lymphoma. JAMA. 2016;315:2115–6.CrossRefGoogle Scholar
  23. 23.
    Huntington SF, Svoboda J, Doshi JA. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission. J Clin Oncol. 2015;33:1467–74.CrossRefGoogle Scholar
  24. 24.
    Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16:541–9.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2020

Authors and Affiliations

  • Takanori Fukuta
    • 1
    Email author
  • Noriko Nishimura
    • 1
  • Yuko Shirouchi
    • 1
  • Norihito Inoue
    • 1
  • Hideki Uryu
    • 1
  • Yoshiharu Kusano
    • 1
  • Yuko Mishima
    • 1
  • Masahiro Yokoyama
    • 1
  • Naoko Tsuyama
    • 2
  • Kengo Takeuchi
    • 2
    • 3
  • Yasuhito Terui
    • 1
  1. 1.Department of Hematology and OncologyThe Cancer Institute, Japanese Foundation for Cancer ResearchTokyoJapan
  2. 2.Division of PathologyThe Cancer Institute, Japanese Foundation for Cancer ResearchTokyoJapan
  3. 3.Pathology Project for Molecular TargetsThe Cancer Institute, Japanese Foundation for Cancer ResearchTokyoJapan

Personalised recommendations